Tidefelt U - Search Results

1

Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells.

Rhedin AS, Tidefelt U, Jönsson K, Lundin A, Paul C. Rhedin AS, et al. Among authors: tidefelt u. Leuk Res. 1993 Mar;17(3):271-6. doi: 10.1016/0145-2126(93)90011-9. Leuk Res. 1993. PMID: 7680736

2

The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin-resistant human leukemia cells (HL-60).

Segura-Aguilar J, Jönsson K, Tidefelt U, Paul C. Segura-Aguilar J, et al. Among authors: tidefelt u. Leuk Res. 1992 Jun-Jul;16(6-7):631-7. doi: 10.1016/0145-2126(92)90013-w. Leuk Res. 1992. PMID: 1635381

3

Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Cancer Chemother Pharmacol. 1991;29(1):7-12. doi: 10.1007/BF00686328. Cancer Chemother Pharmacol. 1991. PMID: 1742852

4

Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.

Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C. Sundman-Engberg B, et al. Among authors: tidefelt u. Cancer Chemother Pharmacol. 1990;25(4):252-6. doi: 10.1007/BF00684881. Cancer Chemother Pharmacol. 1990. PMID: 2295112

5

In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations.

Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. Tidefelt U, et al. Eur J Haematol. 1989 Nov;43(5):374-84. doi: 10.1111/j.1600-0609.1989.tb00323.x. Eur J Haematol. 1989. PMID: 2482193 Clinical Trial.

6

Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.

Paul C, Tidefelt U, Liliemark J, Peterson C. Paul C, et al. Among authors: tidefelt u. Leuk Res. 1989;13(2):191-6. doi: 10.1016/0145-2126(89)90145-8. Leuk Res. 1989. PMID: 2927175

7

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.

Gruber A, Liliemark E, Tidefelt U, Paul C, Björkholm M, Peterson C, Liliemark J. Gruber A, et al. Among authors: tidefelt u. Leuk Res. 1995 Oct;19(10):757-61. doi: 10.1016/0145-2126(95)00061-r. Leuk Res. 1995. PMID: 7500654

8

Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Leuk Res. 1994 Apr;18(4):293-7. doi: 10.1016/0145-2126(94)90032-9. Leuk Res. 1994. PMID: 8170171

9

Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo.

Sundman-Engberg B, Tidefelt U, Gruber A, Paul C. Sundman-Engberg B, et al. Among authors: tidefelt u. Leuk Res. 1993 Apr;17(4):347-52. doi: 10.1016/0145-2126(93)90022-d. Leuk Res. 1993. PMID: 8487583

10

Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo.

Sundman-Engberg B, Tidefelt U, Paul C. Sundman-Engberg B, et al. Among authors: tidefelt u. Eur J Haematol. 1996 Jan-Feb;56(1-2):1-6. doi: 10.1111/j.1600-0609.1996.tb00285.x. Eur J Haematol. 1996. PMID: 8599980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters